Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study

To the Editor: Mechlorethamine (ie, nitrogen mustard) is a skin-directed therapy (SDT) for mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL) used since the mid-1900s, with response rates of 70% to 80%.1-3 Mechlorethamine gel (MG) 0.016% (Valchlor; Helsinn Therapeutics, Iselin, NJ) was United States Food and Drug Administration approved in 2013 (stages IA/IB). PROVe (A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor ®, ClinicalTrials.gov identifier: NCT02296164) was designed to study MG real-world use.

Source: Journal of the American Academy of Dermatology - February 19, 2020 Category: Dermatology Authors: Ellen J. Kim, Larisa Geskin, Joan Guitart, Christiane Querfeld, Michael Girardi, Amy Musiek, David R. Mink, Michael J. Williams, James T. Angello, William L. Bailey Tags: Letter Source Type: research